PILMA shares the Administration’s goal of lowering prescription drug costs for Medicare
beneficiaries and working families. However, we are disappointed in CMS’s decision to
finalize its proposal to subject certain new drug formulations to their predecessor
product’s negotiation timeline in the latest Medicare Drug Price Negotiation Program
final rule.
As detailed in our August comment letter, we believe these changes discourage the
independent research, clinical development and manufacturing investment needed to
bring future products to market.
Since January 2025, biopharmaceutical companies have committed to investing nearly
$600 billion in domestic manufacturing and research operations. Those commitments
depend on a policy environment that rewards innovation and enables manufacturers to
confidently commit to the long-term, capital-intensive projects that support thousands of
jobs for the skilled workers who build and maintain these facilities.
Meaningful affordability for patients and union families will not be achieved by
suppressing innovation. It will only decrease access to cures. Affordability will be
achieved by ensuring savings reach the people who need them, rather than the
middlemen who take more than half of every dollar spent on branded medicines.
PILMA remains committed to being a constructive partner in this effort.